MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ
278.42
+10.63
+3.97%
After Hours: 279.00 +0.58 +0.21% 16:34 06/21 EDT
OPEN
267.09
PREV CLOSE
267.79
HIGH
280.59
LOW
266.97
VOLUME
586.65K
TURNOVER
0
52 WEEK HIGH
299.98
52 WEEK LOW
119.76
MARKET CAP
5.93B
P/E (TTM)
-12.0630
1D
5D
1M
3M
1Y
5Y
Eli Lilly: The Party Is Probably Nearing The End
Seeking Alpha · 2d ago
Tracking John Paulson's Paulson & Company Portfolio - Q1 2024 Update
John Paulson's 13F portfolio value increased to $1.45B with 18 securities, top positions include Madrigal Pharma and Bausch Health. Paulson is best known for his leveraged bets against the real-estate bubble and converted to a Family Office structure in 2020. Stake disposals include SSR Mining, stake increases in Madrigals and NovaGold Resources.
Seeking Alpha · 4d ago
Weekly Report: what happened at MDGL last week (0610-0614)?
Weekly Report · 5d ago
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
NASDAQ · 5d ago
Where Will Madrigal Pharmaceuticals Be in 3 Years?
Madrigal Pharmaceuticals' first medicine, Rezdiffra, is the only approved treatment for a liver disease called metabolic-associated steatohepatitis. Madrigal is in a good position to grow its business. The company's first medicine is due to hit the market in three years. But the company has a lot of competition in the market for the disease.
The Motley Fool · 6d ago
Madrigal Pharmaceuticals: The GLP-1 Threat May Be Overcooked
Seeking Alpha · 06/12 14:16
Wolfe Research Initiates Coverage of Madrigal Pharmaceuticals (MDGL) with Outperform Recommendation
NASDAQ · 06/12 00:20
Madrigal Pharmaceuticals Initiated at Outperform by Wolfe Research
Dow Jones · 06/11 18:48
More
About MDGL
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Webull offers Madrigal Pharmaceuticals Inc stock information, including NASDAQ: MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.